Cetuximab
Established medicineAlso known as Erbitux, Cétuximab, Cetuximabum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal Cancer.
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with… Show full indicationShow less
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. For details, see section 5.1. Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer: in combination with encorafenib and FOLFOX for the first line treatment; in combination with encorafenib in patients who have received prior systemic therapy. For details, see section 5.1, for biomarker-based patient selection, see section 4.2. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck: in combination with radiation therapy for locally advanced disease; in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine7
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology5
- Nature medicine3
- Cancer discovery2
- Nature communications2
- BMC gastroenterology1
- Yaeger R7
- Ciardiello F5
- Desai J5
- Van Cutsem E5
- Kim TW4
- Kopetz S4
- Tabernero J4
- Yoshino T4
- Memorial Sloan Kettering Cancer Center8
- Asan Medical Center3
- Hammersmith Hospital3
- Mayo Clinic3
- National Cancer Center Hospital East3
- University of Campania Luigi Vanvitelli3
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 11 of the same disease areas as Cetuximab in the shared literature.
Studied across 8 of the same disease areas as Cetuximab in the shared literature.
Studied across 6 of the same disease areas as Cetuximab in the shared literature.
Studied across 5 of the same disease areas as Cetuximab in the shared literature.
Studied across 9 of the same disease areas as Cetuximab in the shared literature.
Studied across 6 of the same disease areas as Cetuximab in the shared literature.
Studied across 6 of the same disease areas as Cetuximab in the shared literature.
Studied across 2 of the same disease areas as Cetuximab in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- Regulatory event sources are credited in the Regulatory Timeline above.